ABSTRACT
Although anti-thrombotic therapy has been successful for prevention of deaths from acute myocardial infarction (MI), by far, there are few preventive and therapeutic options for ischemic heart failure (IHF) after MI. Qi-Tai-Suan (QTS) is an oleanolic acid (OA) derivative which once underwent a clinical trial for treating hepatitis. In this study, we investigated the potential cardioprotective effect of QTS on IHF. IHF mouse model was constructed by coronary artery ligation in male C57BL/6J mice, and the protective effects of QTS on IHF were examined by echocardiography measurement, histological and TUNEL analysis, etc. We found that QTS exhibited promising cardioprotective effect on IHF. QTS treatment significantly improved cardiac function of IHF mice and the symptoms of heart failure. Notably, QTS had much better oral bioavailability (F = 41.91%) in mice than its parent drug OA, and took effects mainly as its original form. Mechanistically, QTS ameliorated ischemic heart failure likely through suppression of cardiac apoptosis, inflammation and fibrosis. Taken together, QTS holds great promise as a preventive and therapeutic agent for ischemic heart failure and related diseases.
Subject(s)
Animals , Male , Mice , Apoptosis , Fibrosis , Heart Failure/drug therapy , Inflammation/drug therapy , Mice, Inbred C57BL , Myocardial Ischemia/pathology , Oleanolic Acid/pharmacologyABSTRACT
Hypoxia is one of the most important characteristics of malignant tumor microenvironment, and its degree is closely related to the development and prognosis of the tumor. Hypoxia promotes neovascularization in tumor microenvironment, which leads to changes of energy metabolism and the formation of drug tolerance in tumor. Studies in recent years have shown that TCM can interfere with the occurrence and development of hypoxia tumor microenvironment in certain aspects, thus inhibiting tumor growth. This article summarized recent studies on the etiology, pathogenesis, and TCM intervention for the occurrence and development of hypoxia tumor microenvironment in terms of spleen deficiency, blood stasis, and phlegm retention, and provided a reference for clinical intervention of tumors and research and development of new drugs.
ABSTRACT
<p><b>OBJECTIVE</b>To observe the clinical effect of the combined therapy using argon-helium cryosurgery (Ar-He knife) and Chinese herbal medicine in treating non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>Fifty-seven patients of NSCLC were treated with the combined therapy and observed.</p><p><b>RESULTS</b>The treatment was successfully completed in all patients with mild adverse reactions. The effective rate was 83.8% 3 months after the operation, 79.6% 6 months after the operation, and 77.3% 12 months after the operation, with median survival of 9 months. The survival rate after 12 months was 46.67% (21/45), 34.62% (9/26) after 18 months, and 36.36% (4/11) after 24 months.</p><p><b>CONCLUSION</b>Argon-helium cryosurgery therapy is superior in its assured orientation, quick tumor load deprivation and less postoperational reaction. Combined with Chinese herbal medication, Argon-helium cryosurgery therapy can prolong survival time, relieve clinical symptoms, and elevate the quality of life in NSCLC patients, and is thus worthy of promotion.</p>